{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:56:02Z","timestamp":1760316962719,"version":"build-2065373602"},"reference-count":63,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T00:00:00Z","timestamp":1230681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The combination of a platinating agent and etoposide has induced responses in various pediatric tumors. The study estimated the maximum tolerated dose (MTD) of an oxaliplatin and etoposide regimen in children with recurrent solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Oxaliplatin was administered on Day 1 and etoposide on Days 1 to 3 of each 21\u2010day course. Cohorts of 3 to 6 patients were enrolled at 3 dose levels: 1) oxaliplatin at a dose of 130 mg\/m<jats:sup>2<\/jats:sup> and etoposide at a dose of 75 mg\/m<jats:sup>2<\/jats:sup>, 2) oxaliplatin at a dose of 130 mg\/m<jats:sup>2<\/jats:sup> and etoposide at a dose of 100 mg\/m<jats:sup>2<\/jats:sup>, and 3) oxaliplatin at a dose of 145 mg\/m<jats:sup>2<\/jats:sup> and etoposide at a dose of 100 mg\/m<jats:sup>2<\/jats:sup>. Calcium and magnesium infusions were used at dose level 3 in an attempt to escalate the oxaliplatin dose past the single\u2010agent MTD.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The 16 patients received a total of 63 courses. At dose level 1, dose\u2010limiting epistaxis, neuropathy, and neutropenia occurred in 1 of 6 patients. No dose\u2010limiting toxicity (DLT) occurred at dose level 2 (n = 6). At dose level 3, 2 of 4 patients experienced dose\u2010limiting neutropenia; none experienced grade 3 or 4 acute neuropathy. Six patients required prolongation of the oxaliplatin infusion because of acute sensory neuropathy. Responses were observed in patients with medulloblastoma (1 complete response) and pineoblastoma (1 partial response); 3 others with atypical teratoid rhabdoid tumor, ependymoma, and soft tissue sarcoma had prolonged disease stabilization.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The MTD of this regimen was found to be oxaliplatin at a dose of 130 mg\/m<jats:sup>2<\/jats:sup> given on Day 1 and etoposide at a dose of 100 mg\/m<jats:sup>2<\/jats:sup>\/d given on Days 1 to 3. Neutropenia was found to be the DLT. Calcium and magnesium infusions did not allow escalation of the oxaliplatin dose. The combination was well\u2010tolerated and demonstrated antitumor activity. Cancer 2009. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24054","type":"journal-article","created":{"date-parts":[[2009,1,2]],"date-time":"2009-01-02T05:36:01Z","timestamp":1230874561000},"page":"655-664","source":"Crossref","is-referenced-by-count":10,"title":["Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors"],"prefix":"10.1002","volume":"115","author":[{"given":"Lisa M.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri L.","family":"Spunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred H.","family":"Laningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne L.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199023000-00008"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230506"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2247"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.2.330"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00009"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.10.1592"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.6.941"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.931"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880018709141286"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.598"},{"key":"e_1_2_7_12_2","first-page":"61","article-title":"Etoposide plus carboplatin or cisplatin in good\u2010risk patients with germ cell tumors: a randomized comparison","volume":"21","author":"Bosl GJ","year":"1994","journal-title":"Semin Oncol."},{"key":"e_1_2_7_13_2","first-page":"525","article-title":"Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group","volume":"71","author":"Carli M","year":"1987","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199805)30:5<269::AID-MPO2>3.0.CO;2-D"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.1995.13.4.902","article-title":"Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie Pediatrique","volume":"13","author":"Doz F","year":"1995","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/019459989811800504"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199911000-00016"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000141348.62532.73"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.6.754"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168288"},{"key":"e_1_2_7_21_2","first-page":"S36","article-title":"Cisplatin therapy in infants: short and long\u2010term morbidity","volume":"18","author":"Brock PR","year":"1992","journal-title":"Br J Cancer Suppl."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.6.1441"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.459"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006149809479"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO;2-N"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/2.4.213","article-title":"Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study","volume":"2","author":"Mahoney DH","year":"2000","journal-title":"Neuro Oncol."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/153473540200100301"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005800520747"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00342-6"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)81490-6"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00411-2"},{"key":"e_1_2_7_33_2","first-page":"3579","article-title":"The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum\u2010DNA adducts","volume":"58","author":"Vaisman A","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.58.5.920"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf018"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00684890"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7585"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1193"},{"volume-title":"Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology","year":"1995","author":"Brienza S","key":"e_1_2_7_39_2"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22241"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2388"},{"key":"e_1_2_7_42_2","first-page":"673","article-title":"Interaction of etoposide and cisplatin in an in vitro tumor model","volume":"71","author":"Durand RE","year":"1987","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02994093"},{"key":"e_1_2_7_44_2","first-page":"1459","article-title":"cis\u2010Dichlorodiammineplatinum(II): combination chemotherapy and cross\u2010resistance studies with tumors of mice","volume":"63","author":"Schabel FM","year":"1979","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_7_45_2","first-page":"5663","article-title":"Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin\u2010induced DNA interstrand cross\u2010links and cytotoxicity in human glioblastoma cells","volume":"53","author":"Ali\u2010Osman F","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_7_46_2","first-page":"1425","article-title":"Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule\u2010dependent process","volume":"57","author":"Whitacre CM","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_7_47_2","first-page":"6109","article-title":"DNA topoisomerase II alpha expression is associated with alkylating agent resistance","volume":"55","author":"Eder JP","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_7_48_2","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/jco.2004.22.90140.3749","article-title":"Effect of chemotherapy on topoisomerase (TOP) expression and activity in colon carcinoma cells","volume":"22","author":"Cartei G","year":"2004","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_49_2","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra JM","year":"1998","journal-title":"Semin Oncol."},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.35525"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00667-1"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.85.5.2293"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00435-6"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0666"},{"volume-title":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0","year":"2003","key":"e_1_2_7_55_2"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5251"},{"key":"e_1_2_7_58_2","unstructured":"HochsterHS GrotheyA ShpilskyA ChildsBH.Effect of intravenous (IV) calcium and magnesium (Ca\/Mg) versus placebo on response to FOLFOX + bevacizumab (BEV) in the CONcePT trial. Abstract 280. In: Proceedings of the 2008 Gastrointestinal Cancers Symposium Orlando Florida.2008."},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2390"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0660"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006333811437"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318059c220"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20272"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf058"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24054","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:10:42Z","timestamp":1760299842000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,20]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1002\/cncr.24054"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24054","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2009,1,20]]}}}